Reporthive.com introduced key new research reports encompassing the Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics market. The aim of the study is to provide market leaders with a revolutionary decision-making tool that covers key fundamentals of the Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics market. The Report Covers Market Size, Share, product Segmentation, CAGR,...
finance News
SAN DIEGO – Lassen Therapeutics a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with Cedars Sinai Medical Center. The collaboration will study the role of IL-11 signaling and its inhibition in lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), and the potential therapeutic effect...
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced today that the Company has signed a binding Share Purchase Agreement for the sale to Kedrion S.p.A. (“Kedrion”) of its plasma collection centers operated in Winnipeg, Manitoba and Amherst,...
CARLSBAD, Calif. – Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced a worldwide license and development collaboration agreement with Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. The collaboration...
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the year ended December 31, 2022.
PARIS – Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announces that it has entered into an exclusive, worldwide license agreement with SATT Conectus for the development and commercialization of a gene therapy candidate for the treatment of Fragile X...
LOS ANGELES – Mandos, LLC (Mandos) announced they have entered into an agreement with Vtesse, LLC, a wholly owned subsidiary of Mallinckrodt Pharmaceuticals (Mallinckrodt), a global biopharmaceutical company, to acquire adrabetadex (also known as VTS-270), a drug in development for the treatment of Niemann-Pick Type C1 disease (NPC1). This acquisition,...
NEW YORK, Sept. 10, 2021 /PRNewswire/ — Building on a commitment to educate clinicians on rare diseases, Medscape Education, a leading source of accredited medical education for healthcare professionals (HCPs), has launched Pathways In Rare Disease. This dedicated learning center serves as a centralized location for clinicians who are seeking information about how to...
Cambridge, MA – Merck bumped up its position from shareholder to acquirer in a move to scoop up neurodegenerative disease biotech Caraway Therapeutics for up to $610 million, the pharma giant announced Tuesday. Merck previously invested in Caraway in 2018 through its MRL Ventures Fund, Merck will now acquire all outstanding...
MUNICH, Germany – Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for Skysona™ (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. Today, the European Commission (EC) has granted marketing authorization for...